You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Metabolic conditions

Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]

  • In development
  • Reference number: GID-TA11701
  • Expected publication date: TBC
  • Project information
  • Project documents

On this page

  1. Notes
  2. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6540
  3. Referral

Documents

Documents created during the development process.

Notes

  • Please note that this evaluation has been rescheduled to align more closely with latest regulatory expectations. Therefore, we now anticipate that the evaluation will begin during mid-September 2026 when we will write to you about how to get involved. The deadline for submissions is expected in approximately mid-November 2026.

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6540

  • Draft scope post referral (PDF 139 KB)

    Published:
    04 March 2026
  • Provisional stakeholder list post referral (PDF 140 KB)

    Published:
    04 March 2026

Referral

  • Referral

Back to top